# Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

> **NCT03666325** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 43 (estimated)

## Conditions studied

- Skin Neoplasm

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03666325
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2018-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03666325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03666325, "Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03666325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*